Ampersand Capital Partners invests in GeneWerk

The GP aims to support GeneWerk's growth in order to meet the demand for its services, according to a statement.

US-headquartered Ampersand focuses exclusively on investments in the healthcare sector, specialising in laboratory products, laboratory services, contract manufacturing, pharmaceutical services and speciality pharmaceutical companies.

The GP is currently deploying equity via Ampersand 2020, which held a final close in March 2020 on $690m. The firm's previous investments in Germany include biopharmaceutical products manufacturer Vibalogics in May 2019. 

Ampersand focuses on companies with revenues of $10-100m, deploying equity of $10-100m.

Company
Heidelberg-based GeneWerk provides laboratory and patient testing services for pharmaceutical firms developing gene and cell therapies, including vector safety and immune repertoire analyses. The company was founded in 2014 and has 17 employees, according to LinkedIn.

People
GeneWerk – Annette Deichmann, Manfred Schmidt (co-founders, co-CEOs); Christof von Kalle (co-founder).
Ampersand Capital Partners – Marina Pellon-Consunji (principal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• DACH
• Healthcare
• Germany